Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, announced the completion of a $200 million Series B financing on August 2. As an important investor, LongRiver Investments supports the company’s pipeline progression and expansion for age-related degenerative diseases.
Sironax plans to use the proceeds to support the ongoing clinical development of its portfolio of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors in addition to the continued expansion of its R&D footprint and pipeline of potential best-in-class and first-in-class candidates for age-related degenerative diseases.
“We are pleased to be supported by a syndicate of leading investors to enable us to achieve our vision of bringing transformational therapies to patients around the globe whose lives are impacted by a broad range of degenerative diseases,” said Aaron Ren, Ph.D., Chief Executive Officer of Sironax. “Building upon groundbreaking discoveries—including many by our co-founder Dr. Xiaodong Wang—we have built a robust pipeline of novel programs of both small molecules and biologics that target critical pathways underlying degenerative disease pathogenesis. With this investment, we are well-positioned to advance additional programs into the clinic and continue to move our lead program forward.”
Jiang Zhang, the founder and CEO of LongRiver Investments commented: "According to our research in the global disease spectrum in 2030, we believe there is a huge unmet demand for degenerative diseases. Sironax has the capabilities of continuous breakthrough innovation with strong pipeline, and promising progress in early clinical trials. We are very pleased to establish a long-term cooperative relationship with Dr. Xiaodong Wang, Dr. Aaron Ren, and the Sironax team. LRI will leverage global resources and professional advantages to empower the company to become a next-generation biopharmaceutical leader at a world-class level, to benefit patients around the world."
Series B was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, K2 Venture Partners and lead investors from previous financings. In addition to the co-leads, new investors include LongRiver Investments, MSA Capital, CBC Group, LSV Capital, Superstring Capital, and Future Innovation Fund as well as a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA).
